Boeing Just Sold 3 Businesses in 1 Week. Here's What It Says About the Aerospace Giant's Turnaround.

Boeing agreed to sell three eVTOL/aerospace businesses to Archer Aviation and invest $55M in Archer, targeting a close later this year that would leave Boeing with nearly a 20% stake. While the deal could generate multibillion-dollar value and may reduce distractions, the article argues it’s incremental versus Boeing’s size ($~170B market cap) and that the turnaround upside is already priced in (trading around 77x TTM earnings vs ~40x for GE Aerospace). The FAA approved the 737 MAX 7, but the piece urges waiting for a pullback or clearer evidence of sustained profitability before buying.

Analysis

This is more of a capital-allocation cleanup than a re-rating event. For BA, the economic value of the stake is mostly a long-dated call option on eVTOL, while the stock still trades on near-term execution in commercial delivery rates and cash conversion. That means the announcement can help sentiment for a few sessions, but it is unlikely to move the multiple unless management pairs it with materially better free-cash-flow guidance over the next 1-3 quarters.

ACHR gets the cleaner near-term narrative: a major incumbent effectively validating the platform can improve partner access, hiring, and fundraising optics. But the equity issuance/warrant structure means the market should discount some of the headline value until closing certainty, integration, and certification milestones are visible; in other words, the announcement is positive, but the dilution and execution burden are still the real drivers over the next 3-12 months. The second-order winner may be other aerospace suppliers and software names if the deal accelerates industry consolidation around a few surviving eVTOL platforms.

The contrarian miss is on BA: investors may focus on the optionality value and underweight that the core equity is already priced for a turnaround. Conversely, the market may overstate how much strategic validation flows to ACHR; without a clear path to lower unit economics and financing self-sufficiency, endorsement alone does not eliminate the capital intensity problem. Falsifiers are simple: for BA, sustained upward revision to 2025 FCF and margin guidance; for ACHR, a clean regulatory close plus evidence the deal reduces future dilution rather than merely postponing it.

Key Decisions for Investors

• BA: use any headline-driven rally to trim or hedge rather than add; the stock needs tangible FCF guidance upside, not just balance-sheet optionality, to justify multiple expansion. Thesis is wrong if management raises annual FCF outlook materially above current expectations and delivery cadence stays intact.
• ACHR: keep on a watchlist as a small event-driven long only on post-announcement pullbacks or on confirmation that regulatory approval is progressing; treat the stake/asset transfer as credibility-enhancing but not thesis-completing. Exit if deal approval slips or if the market starts pricing in larger-than-expected dilution.
• Relative-value: favor long ACHR versus an underweight in BA only if the close/approval process is clean and investor messaging shifts to commercialization milestones; otherwise prefer no trade, because ACHR remains financing-sensitive and BA remains turnaround-sensitive.
• Avoid chasing GE on this headline; it is a useful valuation comp, but the event does not change GE's earnings path. Use GE only as a sector barometer for whether aerospace multiple expansion is broadening or staying idiosyncratic.